Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities: 2013-2022

Historic Other financing activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Dec 2022 value amounting to $446,000.

  • Viridian Therapeutics, Inc.\DE's Other financing activities fell 98.47% to $209,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year decrease of 256.45%. This contributed to the annual value of $446,000 for FY2022, which is N/A change from last year.
  • According to the latest figures from FY2022, Viridian Therapeutics, Inc.\DE's Other financing activities is $446,000, which was down 90.85% from $4.9 million recorded in FY2020.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Other financing activities registered a high of $4.9 million during FY2020, and its lowest value of $446,000 during FY2022.
  • Its 2-year average for Other financing activities is $2.7 million, with a median of $2.7 million in 2020.
  • Data for Viridian Therapeutics, Inc.\DE's Other financing activities shows a peak YoY spiked of 149.75% (in 2018) over the last 5 years.
  • Yearly analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Other financing activities stood at $3.0 million in 2018, then followed by $4.9 million in 2020, then followed by $446,000 in 2022.